Safety assessment of the Cistanche tubulosa health food product Memoregain®: Genotoxicity and 28-day repeated dose toxicity test

Po Lin Liao, Ching Hao Li, Ling Shan Tse, Jaw Jou Kang, Yu Wen Cheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacological effects of Cistanches Herba, known as “Ginseng of the desert” have been extensively studied. In this study, we aimed to assess the genotoxic and oral toxic effects of the Cistanche tubulosa health food product Memoregain® using in vitro and in vivo tests. Ames tests using five strains of Salmonella typhimurium showed no signs of increased reverse mutation upon exposure to Memoregain® up to a concentration of 5 mg/plate. Exposure of Chinese hamster ovary (CHO-K1) cells to Memoregain® did not increase the frequency of chromosomal aberrations in vitro. Moreover, Memoregain® treatment did not affect the proportions of immature to total erythrocytes or the number of micronuclei in the immature erythrocytes of ICR mice. Additionally, after 28-day repeated oral dose toxicity tests (0, 0.15, 0.3, and 0.5g/kg body weight) in rats, no observable adverse effects were found. These toxicological assessments supported the safety of Memoregain® for human consumption.

Original languageEnglish
Pages (from-to)581-588
Number of pages8
JournalFood and Chemical Toxicology
Volume118
DOIs
Publication statusPublished - Aug 1 2018

Keywords

  • 28-day repeated oral dose toxicity
  • Cistanche tubulosa
  • Genotoxicity test
  • No-observed-adverse-effect-level

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Fingerprint Dive into the research topics of 'Safety assessment of the Cistanche tubulosa health food product Memoregain<sup>®</sup>: Genotoxicity and 28-day repeated dose toxicity test'. Together they form a unique fingerprint.

  • Cite this